Starting from the screening of a collection of FDA-approved drugs and natural compounds, Li and colleagues identified resveratrol, among others, as a compound able to elicit an increase in frataxin levels (Li et al., 2013) in cells expressing a FXN-EGFP genomic reporter containing a normal copy of the frataxin, as well as in lymphoblasts and fibroblasts derived from FRDA patients, both at the mRNA and protein level. Here, FXN is linked to Friedreich ataxia.